Literature DB >> 18298297

Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.

S M Mansour Haeryfar1.   

Abstract

Although various elements of the immune system are involved in detection and elimination of neoplastic cells, immune surveillance mechanisms are not always successful in eradicating cancer. Invariant natural killer T cells are potent immunomodulatory lymphocytes that secrete large amounts of Th-1 and/or Th-2 cytokines in response to glycolipid agonists. The observed role of invariant natural killer T cells in antitumor immunity in various animal models and the relatively recent identification and availability of Invariant natural killer T cell glycolipid ligands with anticancer properties such as -galactosylceramide have led to several invariant natural killer T cell-based clinical trials in cancer patients with somewhat promising outcomes. The objective of this article is to provide a short overview on immunobiology of invariant natural killer T cells followed by their potential applications in treatment of cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18298297     DOI: 08112/AIM.0012

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  3 in total

1.  Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.

Authors:  Lisa A Mannik; Ian Chin-Yee; Shayan Sharif; Luc Van Kaer; Terry L Delovitch; S M Mansour Haeryfar
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

2.  Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice.

Authors:  Yawei Liu; Anna Teige; Emma Mondoc; Saleh Ibrahim; Rikard Holmdahl; Shohreh Issazadeh-Navikas
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

Review 3.  NKT cell costimulation: experimental progress and therapeutic promise.

Authors:  Marianne J van den Heuvel; Nitan Garg; Luc Van Kaer; S M Mansour Haeryfar
Journal:  Trends Mol Med       Date:  2010-11-17       Impact factor: 11.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.